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Atorvastatin and HMG-CoA reductase inhibitors are the most frequently used medication in the world due to very few adverse
toxic side effects. One potentially life threatening adverse effect is caused by clinically significant statin induced rhabdomyolysis,
either independently or in combination with fusidic acid. The patient in our case who previously had cardiac insufficiency, atrial
fibrillation, and thoracic aorta aneurysm and was treated with insertion of an endovascular metallic stent in the aorta is presented
in the report. He had an inoperable aortitis with an infected stent and para-aortic abscesses with no identified microorganism.The
patient responded well to empirical antibiotic treatment with combination therapy of fusidic acid andmoxifloxacin.This treatment
was planned as a lifelong prophylactic treatment. The patient had been treated with atorvastatin for several years. He developed
severe rhabdomyolysis when he was started on fusidic acid and moxifloxacin. The patient made a fast recovery after termination
of treatment with atorvastatin and fusidic acid. We here report a life threatening complication of rhabdomyolysis that physicians
must be aware of.This can happen either in atorvastatinmonotherapy or as a complication of pharmacokinetic interaction between
atorvastatin and fusidic acid.
1. Introduction
Rhabdomyolysis is most commonly described by “lysis”
or disintegration and breakdown of skeletal muscles and
subsequent release of toxic intracellular components into the
systemic circulation. The major causes of rhabdomyolysis
include trauma, infections, hyperthermia, myopathies, and
adverse drug-drug interactions of certain medications [1].
Statin myotoxicity is a well-known side effect and is related
to serum levels of the drugs and can also be influenced
by coprescription with other drugs, thus increasing the risk
of side effects including rhabdomyolysis [2–4]. Although it
has been reported previously that there is an increased risk
of myopathy with coprescription of atorvastatin and fusidic
acid, it was not before 2011 that the avoidance of coprescrip-
tion of this drug combination was recommended [5–7]. We
present a patient already on statin treatment who developed
rhabdomyolysis apparently precipitated by fusidic acid. The
potential life threatening interaction between atorvastatin
and fusidic acid is highlighted in this case report.
2. Case Presentation
A Caucasian man aged 75 years presented to the Emergency
Department at the National Hospital, Faroe Islands, with
complaints of a two-week history of progressively severe
diffuse myalgia, confined to the lower back and proximal
lower muscles, reduced power in all four extremities, and
generalized weakness, and he was immobile and bedridden.
He was neurologically sound and there was no complaint
regarding headache, numbness, tingling, or paraesthesia. He
denied indulgence in any kind of vigorous physical exercise
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Table 1: Muscle and kidney function biomarkers during the admission. The combination of atorvastatin and fusidic acid stopped at day 6
since admission.
Days
(according to admission)
Creatinine kinase
(normal 40–280U/L)
Myoglobulin
(normal 24–77 ng/L)
Creatinine
(normal 60–105micromole/L)
Urea
(normal 3.5–8.1mmol/L)
1 — — 128 16.8
2 — — — —
3 — — — —
4 — — 119 —
5 10865 — 108 —
6 10750 — 92 —
7 22520 — 134 —
8 35080 — 134 —
9 >20000 26300 100 22.2
10 8070 7110 85 21.8
11 3350 2590 74 19.5
12 1740 — 74 17.0
13 755 — 62 13.3
14 314 — 70 10.4
15 197 143 68 8.1
16 149 89 81 7.7
17 112 94 79 8.0
22 389 — 81 8.0
26 72 — 85 —
29 71 — 85 —
and over consumption of alcohol. He was already under
medication for hypertension and in treatment with rivarox-
aban due to atrial fibrillation and atorvastatin 80mg daily
for hyperlipidaemia and on lifelong prophylactic empirical
antibiotic treatment with oral fusidic acid 500mg twice a
day combined with oral moxifloxacin 400mg daily and for
an infected aortic aneurysm, with an infected endovascular
aortic stent and para-aortic abscesses. He had no familial or
prior personal history of muscle disorder and no past history
of muscular toxicity with statin or fibrate use. He had been
in treatment with atorvastatin for several years. He had been
treated with fusidic acid and moxifloxacin for 6 days before
the day of admission.
He was afebrile with heart rate 75 beats/minute but
hypotensive (103/42mmHg).The cardiovascular, respiratory,
and gastrointestinal tract examination was normal. He com-
plained of moderate discomfort due to myalgia. The quadri-
ceps muscles were tender to palpation and he had reduced
power bilaterally. The cranial nerves 2–12 examination was
normal. The power 5/5 strength in all the muscle groups was
observed, except for the hip flexors and quadriceps which
rated 3/5 bilaterally. He was immobile due to weakness. He
had normal sensory examinations to light touch, pin prick,
and proprioception.
On admission the laboratory measurements revealed the
following: hemoglobin 6.4mmol/L, total leukocyte count
7.8 × 109/L, potassium 4.4mmol/L, sodium 140mmol/L,
urea 16.8mmol/L, creatinine 128micromol/L, and blood
glucose 6.5mmol/L. Serum muscle enzymes were markedly
elevated: creatinine kinase (CK) 328U/L (reference values:
40–208), LDH 266U/L (reference values: 115–255), BNP
607 pmol/L (normal up to 28.9), elevated liver function
test with ALAT 125U/L (reference values: 10–70), alkaline
phosphatases 232U/L (reference values: 35–105), and normal
bilirubin 9U/L (reference values: 5–25). Table 1 describes
the levels of CK, myoglobin, creatinine, and urea (the com-
bination was stopped on 6th day after admission). Urine
analysis showed no significant microscopic hematuria or
proteinuria. The patient was also screened for autoimmune
diseases: autoantibody p-ANCA (IgG) with medium pos-
itive result (nonconclusive), autoantibody c-ANCA (IgG)
negative, and autoantibody ANA negative. These results
made the differential diagnoses immunological vasculitis,
granulomatosis with polyangiitis, and systemic lupus ery-
thematosus (SLE) unlikely. The rheumatological differential
diagnoses polymyositis and dermatomyositis were unlikely
because of negative autoantibodies known to be associated
to polymyositis and dermatomyositis (Table 2). A spinal
tap was performed to rule out Guillain-Barre´ syndrome as
differential diagnosis. The spinal tap showed no pleocytosis,
normal protein, and normal glucose level in the cerebrospinal
fluid. An MRI of the cervical spine showed a nonsignificant
spinal stenosis at the C5/C6 level, which did not explain
the symptomatology of the patient. Finally because of neg-
ative HMG-CoA reductase antibodies (IgG), associated to
autoimmune statin induced rhabdomyolysis, this differential
diagnosis was unlikely in our patient (Table 2). Therefore,
considering the clinical development, the kinetics of the
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Table 2: Screening for autoantibodies known to be associated
to polymyositis, dermatomyositis, and isolated statin (HMG-CoA
reductase inhibitor) causing myalgia.
Antibodies Results
P-Glycyl-tRNA synthetase-Ab. (IgG) Negative
P-Jo 1-antibody (IgG) Negative
P-Histidine-tRNA-ligase (Jo1)-Ab. (IgG) Negative
P-Isoleucyl-tRNA synth. cytop.-Ab. (IgG) Negative
P-MDA5-antibody (IgG) Negative
P-Mi-2a-antibody (IgG) Negative
P-NXP2-antibody (IgG) Negative
P-Polymyositis (Ku)-A (IgG) Negative
P-Polymyositis (PL-12)-antibody Negative
P-Polymyositis (PL-7)-Ab. (IgG) Negative
P-Polymyositis (SRP)-Ab. (IgG) Negative
P-SAE1-antibody (IgG) Negative
P-TIF1 y-antibody (IgG) Negative
HMG-CoA reductase-Ab. (IgG) (HMGCR),
normal reference < 20 <3
biochemical markers, and the medication history, we assume
that the diagnosis of rhabdomyolysis as a consequence to
combination therapy with atorvastatin and fusidic acid is
highly likely. Treatmentwith atorvastatin and fusidic acidwas
halted on 6th day after admission and approximately 12th day
since the combination started. Fusidic acid was changed to
oral Co-amoxiclav 500/125mg tid and the patient continued
on atorvastatin and oral moxifloxacin 400mg daily. The
patient was treated with intravenous fluid and physiotherapy.
The patient was discharged after 5 weeks with remark-
able improvement of symptoms. When he left hospital the
biochemical markers revealed normal muscle enzymes with
CK 71U/L, myoglobin 94 ng/L, and normal transaminases
(Table 1 and Figure 1). It was decided not to treat the patient
with fusidic acid in the future.
3. Discussion
Statins are HMG-CoA inhibitors (hydroxymethylglutaryl/
coenzyme A) and they lower the cholesterol levels by comp-
etitively inhibiting the HMG-CoA reductase, the final path-
way in cholesterol biosynthesis [4, 8]. The three statins (lov-
astatin, simvastatin, and atorvastatin) are metabolized by
the cytochrome p-450 3A4 (CYP-3A4) isoenzymes, whereas
pravastatin is metabolized in the liver by sulfation and fluva-
statin is metabolized by the cytochrome 2C9 isoenzyme
(CYP-2C9) [8].
Rhabdomyolysis is one of the complications of myo-
pathies. The risk of myopathies and rhabdomyolysis is
increased by the concomitant administration of fusidic acid
with statins [4]. Plasma concentration of statins significantly
increases by coadministration of fusidic acid and HMG-CoA
reductase inhibitor [4, 7, 9]. The mechanism of interaction,
whether it is pharmacodynamics or pharmacokinetics or
both, is still unknown. Reports have shown rhabdomyolysis,
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Figure 1: The graph shows the levels of creatinine kinase (CK) and
myoglobulin in the 𝑦-axis and the admission days in the 𝑥-axis.
The rapid fall and normalization of the CK and myoglobulin in our
patient, after cessation of treatment with atorvastatin and fusidic
acid on 6th day prior to admission, clearly suggest the diagnosis of
pharmacokinetic interaction between atorvastatin and fusidic acid
as cause of rhabdomyolysis.
including some fatal cases, in patients receiving combination
of fusidic acid and its salts with oral anticoagulants such
as warfarin, other coumarin derivatives, or anticoagulant;
this may also increase plasma concentration of these anti-
coagulant agents, thus enhancing the anticoagulant effects
with risk of bleeding. An interaction between fusidic acid
and drugs biotransformed via CYP-3A4 system is suspected.
Apparently the mechanism of this interaction is possibly
mutual inhibition of metabolism [9]. However, recent stud-
ies suggest fusidic acid inhibits hepatic transporters and
metabolic enzymes which may cause drug-drug interaction
with statin coadministration [10].
The mortality rate associated with statin induced rhab-
domyolysis is approximately 0.15 deaths per 1 million [4,
11] and it is considered as a rare side effect involving less
than 0.1% of patients on statin treatment. The FDA database
reports a mortality rate of 7.8% in patients with rhabdomy-
olysis [4, 12]. Cerivastatin was previously one of the most
commonly implicated statin [4, 11]. Due tomore than 100 fatal
outcomes linked to rhabdomyolysis, it was withdrawn from
the market in August 2001 [4, 12].
Factors increasing the plasma concentration of the statins
increase the risk of rhabdomyolysis and hepatitis. These
include concomitant use of lipid lowering drugs, hosts genetic
factors, and drug interactions with other medications that
are metabolized by the same cytochrome p-450 system of
enzymes [7, 13]. Risk factors for these adverse effects include
renal disease, hepatic dysfunction, diabetes, age above
80 years, and hypothyroidism [4, 14, 15]. The most common
medications affecting statin metabolism, apart from fusidic
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acid, are fibrates (especially gemfibrozil), cyclosporine, war-
farin, digoxin, macrolides, azole antifungals, calcium channel
blockers, and amiodarone [2, 14–16].
The mainstay treatment of rhabdomyolysis is hydration
and increasing diuresis. Diuresis protects the kidneys by
diluting myoglobin in the renal tubules and hence prevents
the toxic cast formation and also promotes the excretion [17].
Mannitol and urine alkalinization are also indicated in the
treatment of rhabdomyolysis. To our knowledge there are no
specific guidelines, but The American Academy of Clinical
Toxicology and the European Association of Poisons Centre
and Clinical Toxicologists have issued a paper recommend-
ing administration of a bolus of 225mL of 8.4% sodium
bicarbonate intravenously over 1 h, followed by additional
intravenous boluses q. 1 h, to maintain pH between 7.5 and
8.5. Another regimen is to add 1–3 amps (50mEq/50 cc) of
sodium bicarbonate from 8.4% to 0.9% or 0.45% normal
saline or 5%D5W [18]. In all regimes, high recommendations
have been made to monitor the pH, serum potassium, and
arterial pH hourly [7, 19].
4. Conclusion
This case report is highlighting the importance of early recog-
nition and treatment of this rare but potentially fatal side
effect, rhabdomyolysis, caused by use of the statin group
of drugs, either separately or combined with fusidic acid.
If statins are used to treat patients, fusidic acid should not
be used. In conditions where life threatening infection is inv-
olved and fusidic acid is the only antibiotic option available, it
is suggested that all statin treatments should be set on a halt,
as long as the patient is receiving fusidic acid.
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